机构：[1]Department of Dermatology, No.1 Hospital of China Medical University,Shenyang, Liaoning, China[2]Department of Dermatology, First AffiliatedHospital of Kunming Medical College, Kunming, Yunnan, China[3]Department of Dermatology, General Hospital of Shenyang MilitaryCommand, Shenyang, Liaoning, China[4]Department of Surgical Pathology,Affiliated Hospital of Qinghai University, Xining, Qinghai, China[5]Department of Dermatology, Affiliated Hospital of Qinghai University,Xining, Qinghai, China[6]Department of Dermatology, Affiliated GanmeiHospital of Kunming Medical College and The First People’s Hospital ofKunming City, Kunming, Yunnan, China[7]Department of Dermatology,Kangle Hospital, Xining, Qinghai, China[8]Immunology Program, Departmentof Dermatology, Department of Internal Medicine, Henry Ford Health System,Detroit, Michigan, USA[9]Sheftel Associates Dermatology, Tucson, Arizona,USA[10]Pathology Laboratory, Mnazi Mmoja Refferal Hospital, Zanzibar,Tanzania[11]Department of Dermatology, Muhimbili National Hospital,Dar es Salaam, Tanzania
Frequent somatic mutations of BRAF (v-raf murine sarcoma viral oncogene homolog B) exon T1799A, which are implicated in the initial events of promutagenic cellular proliferation, are detected in both malignant melanomas (MM) and melanocytic nevi (MN). Most of the data regarding BRAF exon T1799A mutation have been from Caucasian cohorts, and a comprehensive screening of a homogeneous population is lacking. A total of 379 cases of MN and 195 cases of MM were collected from Chinese Han living in three geographical regions in China, i.e., northeast, southwest, and northwest China. BRAF exon T1799A mutation was detected by PCR and sequencing from microdissected tumors. In all, 59.8% cases of MN harbored BRAF exon T1799A mutation. Samples from regions with high UV exposure had higher detection rates than regions with lower UV exposure (73.5, 67.0, and 38.9%, respectively; chi(2) = 31.674, P = 1.59E-7). There were no differences in mutation rates between congenital and acquired MN; however, acquired MN with advanced age of onset had a higher mutation rate than those with younger age of onset (chi(2) = 13.23, P = 0.02). In all, 15.0% cases of MM harbored the BRAF mutation. The mutation rate in MM was not affected by region, histological type, gender, pattern of UV exposure, and age. The study suggests that the mutation is not necessarily associated with malignant transformation.
基金：
Ministry of Education, ChinaMinistry of Education, China [IRT0760]
第一作者机构：[1]Department of Dermatology, No.1 Hospital of China Medical University,Shenyang, Liaoning, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Dermatology, No.1 Hospital of China Medical University,Shenyang, Liaoning, China[*1]Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, Liaoning, China
推荐引用方式(GB/T 7714)：
Rui-Qun Qi,Li He,Song Zheng,et al.BRAF Exon 15 T1799A Mutation Is Common in Melanocytic Nevi, but Less Prevalent in Cutaneous Malignant Melanoma, in Chinese Han[J].JOURNAL OF INVESTIGATIVE DERMATOLOGY.2011,131(5):1129-1138.doi:10.1038/jid.2010.405.
APA：
Rui-Qun Qi,Li He,Song Zheng,Yuxiao Hong,Lei Ma...&Xing-Hua Gao.(2011).BRAF Exon 15 T1799A Mutation Is Common in Melanocytic Nevi, but Less Prevalent in Cutaneous Malignant Melanoma, in Chinese Han.JOURNAL OF INVESTIGATIVE DERMATOLOGY,131,(5)
MLA：
Rui-Qun Qi,et al."BRAF Exon 15 T1799A Mutation Is Common in Melanocytic Nevi, but Less Prevalent in Cutaneous Malignant Melanoma, in Chinese Han".JOURNAL OF INVESTIGATIVE DERMATOLOGY 131..5(2011):1129-1138
医学